ID: ALA151269

Max Phase: Preclinical

Molecular Formula: C15H21N3O10

Molecular Weight: 403.34

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=CNC[C@H]1O[C@@H](OC[C@H]2O[C@@H](n3ccc(=O)[nH]c3=O)[C@H](O)[C@@H]2O)[C@H](O)[C@@H]1O

Standard InChI:  InChI=1S/C15H21N3O10/c19-5-16-3-6-9(21)12(24)14(28-6)26-4-7-10(22)11(23)13(27-7)18-2-1-8(20)17-15(18)25/h1-2,5-7,9-14,21-24H,3-4H2,(H,16,19)(H,17,20,25)/t6-,7-,9-,10-,11-,12-,13-,14-/m1/s1

Standard InChI Key:  VOIYOBYQJZRYEC-RBUSVLPKSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 403.34

Molecular Weight (Monoisotopic): 403.1227

AlogP: -4.63

#Rotatable Bonds: 7

Polar Surface Area: 192.57

Molecular Species: NEUTRAL

HBA: 11

HBD: 6

#RO5 Violations: 2

HBA (Lipinski): 13

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 9.70

CX Basic pKa:

CX LogP: -3.89

CX LogD: -3.89

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.24

Np Likeness Score: 1.37

References

1. Dini C, Drochon N, Feteanu S, Guillot JC, Peixoto C, Aszodi J..  (2001)  Synthesis of analogues of the O-beta-D-ribofuranosyl nucleoside moiety of liposidomycins. Part 1: contribution of the amino group and the uracil moiety upon the inhibition of MraY.,  11  (4): [PMID:11229763] [10.1016/s0960-894x(00)00715-0]

2. Patel B, Ryan P, Makwana V, Zunk M, Rudrawar S, Grant G..  (2019)  Caprazamycins: Promising lead structures acting on a novel antibacterial target MraY.,  171  [PMID:30933853] [10.1016/j.ejmech.2019.01.071]

Source

Source(1):

• Scientific Literature